By LIANET LEANDRO LÓPEZ
A phase II clinical study for the use of Herberferon against stage III and IV renal carcinoma will begin soon at the Marie Curie Cancer Hospital in the province of Camagüey, where the drug is already applied for basal cell carcinoma (CBC).
According to Iraldo Bello, principal investigator of the drug, informed by the Center for Genetic Engineering and Biotechnology of Havana, next week the initial hearing will be held for the trial in the Camagüey institution, and thereafter the inclusion can begin. of patients.
As criteria for participating in the research, in addition to the advanced stage of the disease, patients must have undergone a nephrectomy or removal of the kidney in the presence of the malignant tumor, specified Bello, leader of the project that favored obtaining the Heberferon from of the combination of two interferons.
So far, 12 patients in Cuba benefit from the novel therapy, with versions of the trial in hospitals Vladimir Ilich Lenin, Holguin, Saturnino Lora, Santiago de Cuba, Arnaldo Milian, Villa Clara, and Joaquín Albarrán, La Havana, said the Doctor of Biological Sciences.
We aspire to reach 270, distributed randomly in three treatment groups, to which the medication would be applied twice a week, he said.
With more than 1,300 patients with CBC treated in the country after its registration in the Basic Table of Drugs in 2016, the Heberferon is expected to prolong the survival of patients with advanced renal carcinomas, even with metastasis, and favor their general condition .
In preliminary studies for this type of cancer have also been reported cases of decreased tumor size, as well as control of metastases, which has allowed patients to coexist with the disease, without losing their quality of life and social activity explained the scientist.
Dr. Bello added that if these results were confirmed in the study, one could aspire to move to a phase III study compared with other immunotherapies, or combining them with the Cuban drug.
Although it is not one of the most frequent locations in malignant tumors, according to the Statistical Yearbook of Health of Cuba of 2018, available on the Internet, renal carcinoma has increased its incidence in the last decade, both in Cuba and in the rest of the world. world, notes on the other hand digital Granma.
Their nonspecific symptoms, or even the absence of signs that indicate their condition, condition late diagnosis in many cases, hence the importance of generating therapies that favor their most appropriate treatment. (ACN)